Core Viewpoint - Anxu Bio (688075.SH) plans to utilize up to RMB 4 billion of its temporarily idle self-owned funds to purchase low-risk, high-liquidity investment products through qualified financial institutions, with a usage period effective from September 18, 2025, for 12 months [1] Group 1 - The company intends to invest in safe and liquid financial products, including but not limited to principal-protected investment products, structured deposits, large-denomination certificates of deposit, and time deposits [1] - The investment will be executed through banks and securities companies that have legal operating qualifications [1] - The funds can be rolled over within the specified limit and duration [1]

7月24日，安旭生物今日收盘41.19元，上涨2.41%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到33.53倍，总市值52.35亿元。 杭州安旭生物科技股份有限公司专注于POCT试剂及仪器的研发、生产与销售。公司主要产品为POCT 试剂及仪器。公司获评"浙江省知识产权示范企业"、"国家知识产权优势企业"。2024年,新增授权专利 44项,其中发明专利13项;累计获得授权专利305项,其中发明专利43项。获得欧盟CE认证、加拿大认证、 澳大利亚认证等多项权威认证证书,新增认证606项,其中,新增国际认证592项,新增国内认证14项,累计已 取得认证1580项。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13安旭生物33.5327.221.0052.35亿行业平均 54.5649.684.73113.96亿行业中值37.5437.872.6253.43亿1九安医疗11.1011.220.87187.29亿2英科医疗 12.5613.541.12198.43亿3新华医疗15.6514.511.28100.34亿4奥美医疗16.1315.801.6658.26亿5振德医疗 16.161 ...

Core Viewpoint - The company announced a cash dividend distribution of 0.8 yuan per share for the fiscal year 2024, totaling approximately 101.67 million yuan for all shareholders [2][4]. Summary by Relevant Sections Dividend Distribution Plan - The profit distribution plan was approved at the annual shareholders' meeting held on May 22, 2025 [2]. - The total share capital before the distribution is 127,082,805 shares, with a total cash dividend of 101,666,244 yuan [4]. Distribution Objects - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the day before the dividend record date [3]. Implementation Method - The dividends for unrestricted circulating shares will be distributed through the clearing system of the China Securities Depository and Clearing Corporation [4]. - Shareholders who have completed designated trading can receive their cash dividends on the distribution date at their designated securities business department [4]. Taxation on Dividends - For individual shareholders holding unrestricted circulating shares for over one year, the cash dividend of 0.8 yuan per share is exempt from personal income tax [8]. - For shares held for one year or less, the tax will be calculated upon the transfer of shares, with a maximum effective tax rate of 20% for shares held for one month or less [8]. - For limited circulating shares, the tax treatment varies, with a post-tax dividend of 0.72 yuan per share for certain categories of shareholders [9][10]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the company's securities department at 0571-85391552 [10].

Core Points - The company announced a cash dividend distribution of 0.8 RMB per share, totaling 101,666,244 RMB based on a total share capital of 127,082,805 shares [1] - The dividend distribution plan was approved at the annual general meeting held on May 22, 2025 [1] - The cash dividend will be distributed to shareholders registered by the end of the trading day on the record date [1] Dividend Distribution Details - The cash dividend of 0.8 RMB per share is inclusive of tax [1] - The distribution will be managed by China Securities Depository and Clearing Corporation Limited, Shanghai Branch [1] - Shareholders who have not completed designated transactions will have their dividends held by the clearing company until the transactions are completed [1] Tax Implications - For individual shareholders holding unrestricted shares for over one year, the dividend income is exempt from individual income tax [3] - For shares held for less than one year, the tax treatment varies: 20% tax for holdings of one month or less, and 10% tax for holdings between one month and one year [3] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, resulting in a net dividend of 0.72 RMB per share [5] - Hong Kong investors will also receive a net dividend of 0.72 RMB per share after a 10% tax withholding [5]

证券代码：688075 证券简称：安旭生物 公告编号：2025-015 杭州安旭生物科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.8元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/17 | 2025/7/18 | 2025/7/18 | 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 22 日的2024年年度股东大会审议通过。 二、分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本127,082,805股为基数，每股派发现 金红利0.8元（含税），共计派发现金红利101,666,244.00元。 三、相关日期 | 股权登记日 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Anxu Biotech, indicating a decline in revenue and profit while comparing its valuation metrics to industry averages [1][2] - Anxu Biotech's closing stock price is 39.22 yuan, with a rolling PE ratio of 31.92, marking a new low in 22 days, and a total market capitalization of 4.984 billion yuan [1] - The company ranks 70th in the medical device industry, which has an average PE ratio of 51.58 and a median of 37.46 [1][2] Group 2 - As of the first quarter of 2025, six institutions hold shares in Anxu Biotech, with a total of 50.3836 million shares valued at 1.998 billion yuan [1] - Anxu Biotech specializes in the research, production, and sales of POCT reagents and instruments, having received multiple certifications including EU CE, Canadian, and Australian certifications [1] - The latest financial report for the first quarter of 2025 shows a revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.0296 million yuan, down 51.52% year-on-year, with a gross margin of 42.32% [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 杭州安旭生物科技股份有限公司（以下简称"安旭生物"或"公司"）董事会首次公开发行股票募集资金按 照相关法律、法规和规范性文件的规定在银行开立了募集资金专项账户。近日，公司办理完成部分募集 资金专用账户的注销手续，现将具体情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会于2021年9月28日出具的《关于同意杭州安旭生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕3138号），公司获准向社会公开发行人民币普通股 15,333,400股，每股发行价格为人民币78.28元，募集资金总额为120,029.86万元；扣除承销及保荐费 用、发行登记费以及其他交易费用共计14,445.23万元（不含增值税金额）后，募集资金净额为 105,584.63万元，上述资金已全部到位，经信永中和会计师事务所（特殊普通合伙）审验并于2021年11 月12日出具了"XYZH/2021HZAA10537"《验资报告》。 募集资金到账后，已全部存放于经公司董事会 批准开 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-014 杭州安旭生物科技股份有限公司 关于部分募集资金账户注销的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安旭生物科技股份有限公司（以下简称"安旭生物"或"公司"）董事会首次 公开发行股票募集资金按照相关法律、法规和规范性文件的规定在银行开立了募集资 金专项账户。近日，公司办理完成部分募集资金专用账户的注销手续，现将具体情况 公告如下： 一、 募集资金基本情况 根据中国证券监督管理委员会于 2021 年 9 月 28 日出具的《关于同意杭州安旭生 物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3138 号），公 司获准向社会公开发行人民币普通股 15,333,400 股，每股发行价格为人民币 78.28 元， 募集资金总额为 120,029.86 万元；扣除承销及保荐费用、发行登记费以及其他交易费 用共计 14,445.23 万元（不含增值税金额）后，募集资金净额为 105,584.63 万元，上述 资金已全部到位，经信永 ...

Company Overview - Anxu Bio focuses on the research, development, production, and sales of POCT reagents and instruments [1] - The company has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of 2024, Anxu Bio has obtained a total of 305 authorized patents, including 43 invention patents [1] Financial Performance - For Q1 2025, Anxu Bio reported a revenue of 115 million yuan, a year-on-year decrease of 10.90% [1] - The net profit for the same period was approximately 34.03 million yuan, reflecting a year-on-year decline of 51.52% [1] - The gross profit margin for the company stood at 42.32% [1] Market Position - Anxu Bio's current price-to-earnings (PE) ratio is 30.77, compared to the industry average of 49.12 and the industry median of 36.07 [2] - The company's total market capitalization is 4.805 billion yuan [1][2] - As of Q1 2025, six institutions hold shares in Anxu Bio, with a total holding of approximately 50.38 million shares valued at 1.998 billion yuan [1]

Company Overview - Anxu Bio focuses on the research, production, and sales of POCT reagents and instruments, and has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of March 31, 2025, Anxu Bio had 5,935 shareholders, a decrease of 278 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Financial Performance - For Q1 2025, Anxu Bio reported revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.03 million yuan, down 51.52% year-on-year, with a gross profit margin of 42.32% [1] Market Position - Anxu Bio's current rolling price-to-earnings (PE) ratio is 30.51, while the average PE ratio for the medical device industry is 49.10, and the industry median is 36.43, placing Anxu Bio at the 69th position in the industry ranking [1][2] - The company's total market capitalization is 4.763 billion yuan [1][2] Intellectual Property and Certifications - In 2024, Anxu Bio added 44 new authorized patents, including 13 invention patents, bringing the total to 305 authorized patents, of which 43 are invention patents [1] - The company has obtained multiple authoritative certifications, including EU CE certification, Canadian certification, and Australian certification, with a total of 1,580 certifications, including 606 new certifications in the latest period [1]